Last reviewed · How we verify

Mary K Hayden — Portfolio Competitive Intelligence Brief

Mary K Hayden pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Povidone Iodine Topical Povidone Iodine Topical marketed Topical antiseptic/disinfectant Microbial cell membranes and proteins (non-selective) Dermatology/Infection Prevention

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Corewell Health East · 1 shared drug class
  2. Jesús María Villar del Moral · 1 shared drug class
  3. Johns Hopkins University · 1 shared drug class
  4. Montefiore Medical Center · 1 shared drug class
  5. Norwegian University of Science and Technology · 1 shared drug class
  6. The Hong Kong Polytechnic University · 1 shared drug class
  7. University of California, Irvine · 1 shared drug class
  8. University of California, Los Angeles · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Mary K Hayden:

Cite this brief

Drug Landscape (2026). Mary K Hayden — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mary-k-hayden. Accessed 2026-05-16.

Related